Monitor future CMS announcements on Exogen reimbursement rates, as further changes could pressure revenue. The reiteration of guidance suggests near-term stability, but the long-term reimbursement trajectory remains uncertain.
Price Chart
Executive Summary
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class III to Class II, and CMS updated billing requirements and the Medicare fee schedule effective May 18, 2026. The company does not expect the reimbursement rate changes to have a material impact on 2026 financial results and is reiterating its prior guidance.
Key Facts
- FDA reclassified non-invasive bone growth stimulators (including Exogen) from Class III to Class II on April 16, 2026.
- CMS updated billing requirements and Medicare fee schedule for HCPCS codes E0747, E0748, E0760 effective May 18, 2026.
- Bioventus does not expect the reimbursement changes to materially impact FY2026 financial results.
- Company is reiterating previously issued 2026 financial guidance.
- Potential future CMS actions could require a revision of financial outlook.
Financial Impact
No material impact expected for FY2026; no specific dollar amounts provided.
Risk Factors
- Future CMS rate cuts could materially reduce Exogen revenue.
- Reclassification may invite competitive entry or additional regulatory requirements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000029 |
| Document: 0001665988-26-000029-index-headers.html | 0001665988-26-000029 |
| Document: 0001665988-26-000029-index.html | 0001665988-26-000029 |
| Document: 0001665988-26-000029.txt | 0001665988-26-000029 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $13.88 $13.16 | ▼ −5.19% | ▼ −3.66% | $13.13 (−5.40%) |
Aug 5, 2026 8w ago | 8-K | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Aug 5, 2026 8w ago | Press Release | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Jun 11, 2026 16w ago | Institutional Cluster | $8.68 $12.22 | ▼ −40.78% | ▼ −38.89% | $13.13 (−51.27%) |
Jun 2, 2026 17w ago | Press Release | $8.11 $9.85 | ▼ −21.45% | ▼ −23.02% | $13.13 (−61.90%) |
May 21, 2026 19w ago | 8-K | $9.28 $8.99 | ▼ −3.13% | ▼ −1.71% | $13.13 (+41.49%) |
May 8, 2026 21w ago | Court Ruling | $10.50 $9.04 | ▼ −13.90% | ▼ −13.93% | $13.13 (+25.05%) |
May 6, 2026 21w ago | 8-K | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
May 6, 2026 21w ago | Press Release | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
Apr 28, 2026 22w ago | Press Release | $9.67 $8.87 | ▼ −8.27% | ▼ −14.32% | $13.13 (+35.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access